Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at ICIEM 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time   BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 5, 2021-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and second quarter 2021 financial results.